HC Wainwright & Co. Maintains Buy on Rani Therapeutics Hldgs, Lowers Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Mitchell Kapoor maintains a Buy rating on Rani Therapeutics Hldgs (NASDAQ:RANI) but lowers the price target from $16 to $12.

March 25, 2024 | 10:06 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. maintains a Buy rating on Rani Therapeutics Hldgs but lowers the price target from $16 to $12.
While the maintenance of a Buy rating indicates continued confidence in Rani Therapeutics Hldgs' potential, the reduction in the price target could reflect adjustments in valuation metrics or market conditions. This mixed signal might lead to short-term uncertainty among investors, balancing out potential positive and negative impacts on the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100